We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+12.87%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$70.9M
(+20%)
Cap. Flow
+$79.1M
Cap. Flow
% of AUM
18.34%
Top 10 Holdings %
Top 10 Hldgs %
23.13%
Holding
178
New
54
Increased
29
Reduced
23
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xtant Medical Holdings
XTNT
|
+$14.7M |
| 2 |
Palisade Bio
PALI
|
+$11M |
| 3 |
POL.WS
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
|
+$10.1M |
| 4 |
electroCore
ECOR
|
+$8.6M |
| 5 |
KLR
Kaleyra, Inc.
KLR
|
+$8.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
|
+$8.32M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$5.67M |
| 3 |
Sutro Biopharma
STRO
|
+$5.16M |
| 4 |
MBTCU
Nocturne Acquisition Corporation Unit
MBTCU
|
+$5M |
| 5 |
Imunon
IMNN
|
+$4.83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.75% |
| 2 | Financials | 3.74% |
| 3 | Technology | 1.96% |
| 4 | Consumer Discretionary | 0.54% |
| 5 | Industrials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
POL.WS
1
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
| $14.7M | 3.42% |
+6,886,600
| New | +$10.1M |
|
|
2
Xtant Medical Holdings
XTNT
$59.7M
| $13.5M | 3.14% |
+8,292,602
| New | +$14.7M |
|
3
Protagonist Therapeutics
PTGX
$8.8B
| $12.7M | 2.94% |
282,445
+44,091
| +18% | +$1.46M |
|
4
Crinetics Pharmaceuticals
CRNX
$8.88B
| $10M | 2.33% |
533,033
+171,103
| +47% | +$3.01M |
|
5
Aldeyra Therapeutics
ALDX
$95.3M
| $9.79M | 2.27% |
864,020
+315,795
| +58% | +$3.8M |
|
|
CTIC
6
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $9.2M | 2.13% |
3,678,677
+3,089,685
| +525% | +$7.41M |
|
|
KLR
7
DELISTED
Kaleyra, Inc.
KLR
| $7.83M | 1.82% |
+182,857
| New | +$8.24M |
|
|
RCOR
8
DELISTED
Renovacor, Inc.
RCOR
| $7.51M | 1.74% |
753,874
+500
| +0.1% | +$5.04K |
|
|
9
Palisade Bio
PALI
$351M
| $7.43M | 1.72% |
+2,433
| New | +$11M |
|
10
Verastem
VSTM
$547M
| $6.98M | 1.62% |
142,966
-71,469
| -33% | -$2.98M |
|
11
Curis
CRIS
$9.41M
| $6.69M | 1.55% |
2,073
+143
| +7% | +$646K |
|
12
Lantheus
LNTH
$6.68B
| $6.63M | 1.54% |
240,066
-35,000
| -13% | -$803K |
|
13
Arcutis Biotherapeutics
ARQT
$3.55B
| $6.31M | 1.46% |
231,314
+117,352
| +103% | +$3.31M |
|
|
EPIX
14
DELISTED
ESSA Pharma
EPIX
| $6.1M | 1.41% |
213,528
-16,535
| -7% | -$481K |
|
|
15
electroCore
ECOR
$50.5M
| $5.95M | 1.38% |
+333,667
| New | +$8.6M |
|
16
Verrica Pharmaceuticals
VRCA
$92.8M
| $5.93M | 1.38% |
52,513
-3,782
| -7% | -$458K |
|
|
KDNY
17
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.88M | 1.36% |
416,567
+210,768
| +102% | +$3.37M |
|
|
SYRS
18
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $5.87M | 1.36% |
107,694
+95,024
| +750% | +$5.62M |
|
19
CareDx
CDNA
$1.85B
| $5.8M | 1.35% |
63,434
-17,850
| -22% | -$1.42M |
|
20
Insmed
INSM
$22.6B
| $5.79M | 1.34% |
203,354
+93,100
| +84% | +$2.76M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.7M | 1.32% |
902,633
| – | – |
|
|
BLU
22
DELISTED
BELLUS Health Inc.
BLU
| $5.56M | 1.29% |
1,788,789
+215,400
| +14% | +$823K |
|
23
Globus Medical
GMED
$10.9B
| $5.49M | 1.27% |
70,833
+21,971
| +45% | +$1.56M |
|
24
CytomX Therapeutics
CTMX
$701M
| $5.46M | 1.27% |
862,417
+379,376
| +79% | +$2.95M |
|
25
Myriad Genetics
MYGN
$502M
| $5.24M | 1.21% |
171,242
-543
| -0.3% | -$15.7K |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Altium Capital Management held 178 positions worth $431M, up 20% from $360M the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Altium Capital Management deployed $79.1M of net new capital in Q2 2021, opening 54 new positions and adding to 29 existing holdings. Its largest new stake was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Verastem, an estimated $2.98M trimmed.
- Altium Capital Management's largest Q2 2021 buy was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.
- Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2021, an estimated $7.41M increase.
- Altium Capital Management's biggest Q2 2021 reduction was Verastem, cutting an estimated $2.98M.
- Altium Capital Management fully exited Biora Therapeutics, Inc. Common Stock in Q2 2021, selling an estimated $8.32M.
- Altium Capital Management's ten largest holdings make up 23% of its $431M portfolio in Q2 2021.
- Altium Capital Management opened 54 new positions and closed 43 in Q2 2021.
- Altium Capital Management's portfolio value rose 20% quarter-over-quarter to $431M.
Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.